3-(5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
• 英文别名: 3-[5-oxo-3-(trifluoromethyl)-4H-pyrazol-1-yl]benzoic Acid
• 化学式: C₁₁H₇F₃N₂O₃
• mdl: MFCD05625688
• 分子量: 272.183
• InChiKey: DRVYMTGABJBCSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(5-甲酰基-呋喃-2-基)-苯甲酸 、 3-(5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid 在 sodium acetate 、 溶剂黄146 作用下， 反应 3.0h， 以4%的产率得到2-(5-((1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)furan-2-yl)benzoic acid
  参考文献：
  名称：

  Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors

  摘要：

  Severe acute respiratory syndrome (SARS) led to a life-threatening form of atypical pneumonia in late 2002. Following that, Middle East Respiratory Syndrome (MERS-CoV) has recently emerged, killing about 36% of patients infected globally, mainly in Saudi Arabia and South Korea. Based on a scaffold we reported for inhibiting neuraminidase (NA), we synthesized the analogues and identified compounds with low micromolar inhibitory activity against 3CL(pro) of SARS-CoV and MERS-CoV. Docking studies show that a carboxylate present at either R-1 or R-4 destabilizes the oxyanion hole in the 3CL(pro). Interestingly, 3f, 3g and 3m could inhibit both NA and 3CL(pro) and serve as a starting point to develop broad-spectrum antiviral agents. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.013

文献信息

• [EN] XPA INHIBITOR COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS INHIBITEURS DE XPA ET LEUR UTILISATION
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2019060260A1

  公开（公告）日：2019-03-28

  The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.

  本公开涉及具有与XPA结合亲和力的某些化合物及其用途。具体而言，本公开涉及在治疗癌症的方法中使用如此描述的XPA抑制剂。
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Muto Susumu

  公开号：US20070276011A1

  公开（公告）日：2007-11-29

  A medicament having inhibitory activity against plasminogen activator inhibitor-1, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein R 1 and R 2 represents an aromatic group which may be substituted, W represents a group selected from the following connecting group W-1: (wherein a bond at the left end binds to the carbon atom and a bond at the right end binds to the nitrogen atom, X represents sulfur atom or NH, Y represents oxygen atom or sulfur atom, R 3 represents a hydrocarbon group, hydroxy group, or carboxy group), Z represents a single bond or a connecting group wherein a number of atoms in a main chain is 1 to 3.

  一种具有抑制纤溶酶原激活物抑制剂-1活性的药物，其包含以下通式（I）或其盐作为活性成分的化合物：其中R1和R2代表可以被取代的芳香基团，W代表以下连接基团之一：（其中左端的键结合到碳原子，右端的键结合到氮原子，X代表硫原子或NH，Y代表氧原子或硫原子，R3代表烃基团，羟基或羧基），Z代表单键或连接基团，其中主链中的原子数为1到3。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR
  申请人：Institute of Medicinal Molecular Design, Inc.

  公开号：EP1666469A1

  公开（公告）日：2006-06-07

  A medicament having inhibitory activity against plasminogen activator inhibitor-1, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein R1 and R2 represents an aromatic group which may be substituted, W represents a group selected from the following connecting group W-1: (wherein a bond at the left end binds to the carbon atom and a bond at the right end binds to the nitrogen atom, X represents sulfur atom or NH, Y represents oxygen atom or sulfur atom, R3 represents a hydrocarbon group, hydroxy group, or carboxy group), Z represents a single bond or a connecting group wherein a number of atoms in a main chain is 1 to 3.

  一种对纤溶酶原激活物抑制剂-1 具有抑制活性的药物，其活性成分包括下式（I）所代表的化合物或其盐： 其中 R1 和 R2 代表可被取代的芳香基团、 W 代表选自下列连接基 W-1 的基团： (其中左端的键与碳原子结合，右端的键与氮原子结合、 X 代表硫原子或 NH Y 代表氧原子或硫原子、 R3 代表烃基、羟基或羧基）、 Z 代表单键或连接基团，其中主链中的原子数为 1 至 3。
• XPA inhibitor compounds and their use
  申请人：INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

  公开号：US11207296B2

  公开（公告）日：2021-12-28

  The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.

  本公开涉及某些对 XPA 具有结合亲和力的化合物及其用途。 具体而言，本公开涉及本文所述的 XPA 抑制剂在治疗癌症方法中的用途。
• Identification, Synthesis, and Evaluation of New Neuraminidase Inhibitors
  作者：Vathan Kumar、Chih-Kang Chang、Kian-Pin Tan、Young-Sik Jung、Shih-Hsun Chen、Yih-Shyun E. Cheng、Po-Huang Liang

  DOI：10.1021/ol502410x

  日期：2014.10.3

  High-throughput screening was performed on similar to 6800 compounds to identify KR-72039 as an inhibitor of H1N1 and H5N1 neuraminidases (NAs). Structureactivity relationship studies led to 3e, which inhibited H5N1 NA with an IC50 of 2.8 mu M and blocked viral replication. Docking analysis shows that compounds bind to loop-430 around the NA active site. Compound 3l additionally inhibited H7N9 NA, making it a dual inhibitor of N1- and N2-type NAs.